Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Virginia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Virginia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 5309 Florida 4445 Illinois 2491 Georgia 2363 Arizona 2246
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca18 Merck Sharp & Dohme LLC13 AbbVie8 Janssen Research & Development, LLC8 Gilead Sciences7
State
California5309 Florida4445 Illinois2491 Georgia2363 Arizona2246
All 51 states
Target enrolment
to

Trials with a site in Virginia

485 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Hoffmann-La Roche
Phase 3
1,600
California, Florida, New York, Virginia
2026-11-30
Not yet open
argenx
Phase 2
120
Florida, Texas, Virginia
2026-10-15
Not yet open
Pfizer
Phase 3
600
Florida, Minnesota, Nevada, Ohio, Oregon, Tennessee, Texas, Virginia
2026-10-09
Not yet open
ModernaTX, Inc.
Phase 1
96
California, Colorado, Minnesota, Ohio, Texas, Virginia
2026-10-07
Recruiting
Medtronic MiniMed, Inc.
Not applicable
1,500
California, Colorado, Connecticut, Florida, Georgia, Idaho, Texas, Virginia
2026-10
Not yet open
Eli Lilly and Company
Phase 2
50
Alabama, California, Florida, Massachusetts, New Jersey, Texas, Virginia, Wisconsin
2026-10
Recruiting
Hoffmann-La Roche
Phase 3
600
California, Virginia
2026-09-30
Recruiting
Novartis Pharmaceuticals
Phase 2
180
Alabama, California, Florida, Kansas, Maryland, Texas, Virginia
2026-09-18
Recruiting
Amphista Therapeutics Ltd
Phase 1
54
Virginia
2026-09-16
Not yet open
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
NCT07807345Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
285
California, Florida, Massachusetts, Oklahoma, Texas, Virginia
2026-09-14
Recruiting
A Study of AWT020 in Participants With Advanced Solid Tumors
NCT07822919Advanced Cancers (Solid Tumors)
DrugAWT020
Anwita Biosciences
Phase 1
96
Florida, Virginia
2026-09-11
Recruiting
Johnson & Johnson Vision Care, Inc.
Not applicable
150
Florida, Illinois, New York, Ohio, Tennessee, Texas, Virginia
2026-09-10
Recruiting
Johnson & Johnson Vision Care, Inc.
Not applicable
150
Florida, Georgia, Missouri, New York, Rhode Island, Tennessee, Texas, Virginia
2026-09-10
Recruiting
JCR Pharmaceuticals Co., Ltd.
Phase 1/2
12
California, Pennsylvania, Virginia
2026-09-09
Recruiting
Biogen
Phase 3
90
California, Virginia
2026-09-08
Recruiting
TwoStep Therapeutics, Inc.
Phase 1
74
Ohio, Oregon, Virginia
2026-09-02
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
392
New York, Virginia
2026-09-02
Not yet open
ModernaTX, Inc.
Phase 2
300
California, Florida, Illinois, Michigan, Ohio, Texas, Utah, Virginia
2026-09-01
Recruiting
Recursion Pharmaceuticals Inc.
Phase 1/2
90
Michigan, Texas, Virginia
2026-09
Not yet open
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT07325214Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer
IMGT Co., Ltd.
Not applicable
360
Massachusetts, Texas, Virginia
2026-09
Recruiting
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
NCT07807163Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsFicerafusp alfa·Keytruda·Pembrolizumab
Bicara Therapeutics
Phase 2
160
Florida, Louisiana, Texas, Virginia
2026-09
Recruiting
AbbVie
Phase 3
300
California, Florida, Idaho, Indiana, Nebraska, Ohio, Texas, Virginia
2026-08-24
Recruiting
Amgen
Phase 3
126
California, Illinois, Virginia
2026-08-21
Not yet open
First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors
NCT07686068Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc
Phase 1/2
260
Texas, Utah, Virginia
2026-08-18
Recruiting
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
NCT07784959ALK Positive, ALK Positive Non-small Cell Lung Cancer, NSCLC, ALK+ Non-Small-Cell Lung Carcinoma
DrugsNXP900·Lorlatinib
Nuvectis Pharma, Inc.
Phase 1
54
Virginia
2026-08-17
Recruiting
SOTIO Biotech a.s.
Phase 1/2
100
Texas, Virginia
2026-08-12
Recruiting
Novo Nordisk A/S
Phase 3
285
Georgia, Hawaii, Illinois, Indiana, Kentucky, North Carolina, South Carolina, Virginia
2026-08-04
Recruiting
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc
DrugsEtoposide·Atezolizumab·Carboplatin
SystImmune Inc.
Phase 3
550
Arkansas, California, Florida, New Jersey, Virginia
2026-08-04
Recruiting
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
NCT07516093B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsBexobrutideg·Pirtobrutinib
Nurix Therapeutics, Inc.
Phase 3
620
Georgia, Indiana, Tennessee, Texas, Virginia
2026-08-03
Recruiting
Cryoablation for Monomorphic Ventricular Tachycardia (VTS)
NCT07650032Ventricular Tachycardia, Sustained, Ventricular Tachycardia, Monomorphic
Adagio Medical
Not applicable
100
Arizona, California, Massachusetts, New York, Pennsylvania, South Carolina, Tennessee, Virginia
2026-08-01
Not yet open
A Phase 1/2 Study to Evaluate the Safety and Efficacy of Dibotatug (DR-01) in Adults With Bone Marrow Failure Syndromes
NCT07712562Bone Marrow Failure Syndromes, Aplastic Anemias, Severe Aplastic Anemia (SAA), Severe Aplastic Anemia, Relapse
DrugDibotatug
Dren Bio
Phase 1/2
60
California, Florida, Georgia, New York, Ohio, Texas, Virginia, Washington
2026-08
Not yet open
Crossbow Therapeutics, Inc.
Phase 1
120
Virginia
2026-08
Recruiting
VelaVigo Bio Inc
Phase 1/2
230
California, Michigan, New York, Texas, Virginia
2026-07-30
Recruiting
Biogen
Phase 2
60
Arizona, California, Florida, Maryland, New Jersey, North Carolina, Texas, Virginia
2026-07-30
Recruiting
Arvinas Inc.
Phase 1/2
499
New York, North Carolina, Texas, Virginia
2026-07-29
Recruiting
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
NCT07755436Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer
ArriVent BioPharma, Inc.
Phase 1
180
Florida, Massachusetts, Tennessee, Texas, Virginia
2026-07-23
Recruiting
A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3
NCT07807241Advanced and/or Metastatic Solid Tumors Known to Express B7-H3
Myricx Pharma Limited
Phase 1
120
Florida, Texas, Virginia
2026-07-20
Recruiting
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
NCT07529808Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma
BigHat Biosciences, Inc.
Phase 1/2
164
California, Virginia
2026-07-16
Recruiting
Gilead Sciences
Phase 3
590
California, Florida, Georgia, Michigan, Missouri, Texas, Virginia, Washington
2026-07-14
Recruiting
Gilead Sciences
Phase 3
590
Michigan, Virginia
2026-07-14
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1/2
294
Virginia
2026-07-10
Recruiting
DePuy Synthes Products, Inc.
Observational
100
Virginia
2026-07-07
Recruiting
Abbott Medical Devices
Observational
1,000
Arizona, California, Illinois, Texas, Virginia
2026-07-02
Not yet open
Cosmos Rx, Inc
Observational
100
Virginia
2026-07
Recruiting
Nefro Avillion Clinical Development, LLC
Phase 2
120
California, Florida, Georgia, Massachusetts, Michigan, New Jersey, Texas, Virginia
2026-06-29
Recruiting
A Study of ARC-02 in B-cell NHL
NCT07691606B-cell Non Hodgkin Lymphoma
DrugRituximab
Taiho Oncology, Inc.
Phase 1
140
California, Kentucky, New York, North Carolina, Virginia, Washington, Wisconsin
2026-06-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
310
Illinois, Nebraska, New York, North Carolina, Virginia
2026-06-18
Recruiting
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
NCT07484022Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
DrugsEnfortumab Vedotin·Pembrolizumab
Generate Biomedicines
Phase 1
37
California, Florida, Georgia, Illinois, New Jersey, New York, Texas, Virginia
2026-06-08
Recruiting
Francis Medical Inc.
Observational
2,500
Louisiana, Minnesota, Texas, Virginia
2026-06-05
Recruiting
Castle Biosciences Incorporated
Observational
450
Arizona, Maryland, Michigan, Missouri, Nevada, New Hampshire, Texas, Virginia
2026-06-04
Not yet open
A System to Help With Freezing of Gait in Parkinson's Patients
NCT07542743Freezing of Gait Symptoms in Parkinson Disease
Barron Associates, Inc.
Not applicable
60
Virginia
2026-06-01
Recruiting
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT07524322Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation
Regor Pharmaceuticals Inc.
Phase 1
63
California, Texas, Virginia
2026-06
Recruiting
Vericel Corporation
Phase 3
309
California, District of Columbia, Kansas, North Carolina, Texas, Virginia
2026-05-28
Recruiting
HTIC, Inc
Phase 1
24
Virginia
2026-05-28
Recruiting
PharmaMar
Phase 1/2
119
New York, Texas, Virginia
2026-05-21
Not yet open
Novo Nordisk A/S
Phase 3
1,000
Florida, Georgia, Idaho, Maryland, Michigan, Texas, Virginia
2026-05-20
Recruiting
Gilead Sciences
Phase 2
170
Connecticut, Massachusetts, Missouri, South Dakota, Virginia
2026-05-19
Recruiting
Jubaan Ltd.
Not applicable
1,436
Alabama, California, Florida, Illinois, New York, Ohio, Virginia
2026-05-18
Recruiting
Denali Therapeutics Inc.
Phase 1
32
California, Missouri, North Carolina, Virginia
2026-05-12
Recruiting
A Study of TAK-505 in Adults With Solid Tumors
NCT07436728Malignant Solid Tumors
Takeda
Phase 1/2
151
California, Florida, Minnesota, New York, Ohio, Tennessee, Texas, Virginia
2026-05-11
Recruiting
Theranica
Not applicable
100
Delaware, Mississippi, New York, Virginia
2026-05-04
Recruiting
NextPoint Therapeutics, Inc.
Phase 1
81
California, Maryland, New York, Tennessee, Texas, Virginia
2026-05-01
Recruiting
Biomea Fusion Inc.
Phase 2
60
Alabama, California, Florida, Georgia, Nevada, Ohio, Texas, Virginia
2026-04-30
Recruiting
AbbVie
Phase 2/3
900
Connecticut, Illinois, Michigan, Missouri, Ohio, Pennsylvania, Texas, Virginia
2026-04-30
Recruiting
Biogen
Phase 3
30
Illinois, Texas, Virginia
2026-04-28
Recruiting
Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer
NCT07493512Metastatic Castration-resistant Prostate Cancer (mCRPC)
DrugXaluritamig
Amgen
Phase 1
40
Colorado, North Carolina, Ohio, Pennsylvania, South Dakota, Tennessee, Texas, Virginia
2026-04-28
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
356
California, New Jersey, Texas, Virginia
2026-04-28
Recruiting
A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors
NCT07612189Locally Advanced (Unresectable) or Metastatic Solid Tumors
NEOK Bio, Inc.
Phase 1
155
Florida, New York, Tennessee, Texas, Virginia
2026-04-22
Recruiting
Genentech, Inc.
Phase 1
93
Arizona, California, Florida, Maryland, Pennsylvania, Tennessee, Texas, Virginia
2026-04-21
Recruiting
Amgen
Phase 1
160
Arizona, Florida, Illinois, Minnesota, New York, Tennessee, Virginia
2026-04-21
Recruiting
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
NCT07612176Locally Advanced (Unresectable) or Metastatic Solid Tumors
NEOK Bio, Inc.
Phase 1
155
New York, Tennessee, Texas, Virginia
2026-04-21
By invitation
Biogen
Phase 3
201
California, Minnesota, Missouri, Nebraska, New Jersey, Ohio, Pennsylvania, Virginia
2026-04-16
Recruiting
Oculis
Phase 2/3
160
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Virginia
2026-04-16
Recruiting
AskBio Inc
Phase 1/2
12
Arizona, California, New York, North Carolina, Pennsylvania, Texas, Virginia
2026-04-15
Recruiting
Janssen Research & Development, LLC
Phase 1
170
Connecticut, Florida, Massachusetts, Tennessee, Texas, Virginia
2026-04-09
Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
Pfizer
Phase 1
250
Colorado, Connecticut, Tennessee, Virginia
2026-04-08
Recruiting
Pfizer
Phase 3
1,712
Maine, Massachusetts, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia
2026-04-08
Recruiting
AI-CARE: Artificial Intelligence for Cardiovascular Analysis and Risk Evaluation
NCT07438327Aortic Aneurysm, Aortic Aneurysm Abdominal, Aortic Aneurysm and Dissection, Aortic Aneurysm, Thoracoabdominal
Aiatella Oy
Observational
250
North Carolina, Virginia
2026-03-31
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
118
District of Columbia, Florida, Kentucky, Texas, Virginia
2026-03-31
Recruiting
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
NCT07454642Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
Avacta Life Sciences Ltd
Phase 1
174
Arizona, Florida, Illinois, Michigan, New York, Texas, Virginia
2026-03-31
By invitation
Fulcrum Therapeutics
Phase 2
50
Arkansas, California, Louisiana, Massachusetts, New York, Texas, Virginia
2026-03-30
Recruiting
Vanda Pharmaceuticals
Phase 3
280
California, Florida, New Jersey, New York, Texas, Virginia
2026-03-27
Recruiting
A 2-part Phase 1/2 Open-label Trial on ODM-212
NCT07563738Mesothelioma, Pancreatic Cancer, NSCLC (Advanced Non-small Cell Lung Cancer)
DrugsODM-212·Gemcitabine and nab-paclitaxel·Ipilimumab and nivolumab·Sotorasib
Orion Corporation, Orion Pharma
Phase 1/2
229
Texas, Virginia
2026-03-27
Active, closed
Biomea Fusion Inc.
Phase 2
64
Alabama, California, Florida, Georgia, Nevada, Ohio, Texas, Virginia
2026-03-27
Recruiting
Samsung Bioepis Co., Ltd.
Phase 1
149
Arizona, Virginia
2026-03-23
Recruiting
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
NCT07540572ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
DrugFulvestrant
IDEAYA Biosciences
Phase 1
160
Florida, New Jersey, New York, Texas, Utah, Virginia
2026-03-17
Recruiting
AstraZeneca
Phase 1/2
180
New York, Rhode Island, Texas, Virginia
2026-03-17
Recruiting
Novaliq GmbH
Phase 2
20
Arizona, Florida, Massachusetts, New Jersey, Texas, Virginia
2026-03-16
Recruiting
Regeneron Pharmaceuticals
Phase 2
34
Arizona, California, Connecticut, Florida, Oregon, Pennsylvania, Texas, Virginia
2026-03-11
By invitation
MDR - PMCF Study for RingLoc Bipolar Acetabular Cup and Endo II Femoral Heads
NCT05199870Hip Arthritis, Hip Disease, Hip Fractures, Hip Injuries
Zimmer Biomet
Observational
116
Virginia
2026-03-10
Recruiting
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
NCT07584226Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors, NRAS Mutation, NRAS G12D
Relay Therapeutics, Inc.
Phase 1
35
California, Colorado, Massachusetts, Michigan, New York, Tennessee, Virginia
2026-03-09
Recruiting
GlaxoSmithKline
Phase 1
225
Alabama, Arkansas, California, Florida, Georgia, Texas, Virginia, Washington
2026-03-09
Recruiting
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
NCT07424547Cancer, Solid Tumor Cancer, Advanced Metastatic Cancer, Prostate
DrugSYS6043
Conjupro Biotherapeutics, Inc.
Phase 1
386
Florida, Texas, Virginia
2026-03-03
Recruiting
Janssen Research & Development, LLC
Phase 1/2
60
New York, Virginia
2026-03-03
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
180
California, Connecticut, Florida, Missouri, New York, Virginia
2026-03-02
Not yet open
Icarus Medical Innovations
Not applicable
150
Virginia
2026-03-01
Recruiting
COPD Exacerbation Follow Up
NCT07118306COPD (Chronic Obstructive Pulmonary Disease)
Viz.ai, Inc.
Observational
485
Illinois, New Jersey, Pennsylvania, Virginia, Wisconsin
2026-02-27
Active, closed
Ipsen
Phase 3
309
Alabama, Arizona, California, Florida, Maryland, South Carolina, Texas, Virginia
2026-02-27
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
Colorado, Florida, Michigan, New York, Tennessee, Texas, Utah, Virginia
2026-02-24
Recruiting
Nuvaira, Inc.
Not applicable
200
Alabama, Florida, Michigan, North Carolina, Ohio, Pennsylvania, Virginia, Wisconsin
2026-02-24
Recruiting
A Study of BI 3810944 in Patients With Advanced Cancer
NCT07224425Solid Tumours, Melanoma
Boehringer Ingelheim
Phase 1
69
Kentucky, Tennessee, Texas, Virginia
2026-02-24
Recruiting
McGuire Institute
Not applicable
72
California, Connecticut, Massachusetts, Nebraska, Texas, Virginia
2026-02-19
Recruiting
Amicus Therapeutics
Observational
450
Alabama, Arkansas, Georgia, Missouri, New York, Pennsylvania, Texas, Virginia
2026-02-13
Recruiting
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
NCT07285785Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
DrugRifaximin
Bausch Health Americas, Inc.
Phase 4
54
California, Florida, Georgia, Illinois, Oregon, Texas, Virginia
2026-02-11
Recruiting
Eli Lilly and Company
Phase 3
300
Colorado, Florida, Pennsylvania, Texas, Virginia
2026-02-05
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1/2
428
New Jersey, New York, Tennessee, Virginia
2026-02-05
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
DrugsElironrasib·Zoldonrasib·Ivonescimab·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
370
California, Connecticut, Minnesota, Tennessee, Texas, Virginia
2026-01-30
Active, closed
Pacagen, Inc.
Not applicable
190
New Jersey, Virginia
2026-01-26
Recruiting
AbbVie
Phase 2
165
Alabama, Florida, Illinois, Michigan, Missouri, Pennsylvania, Virginia
2026-01-23
Recruiting
Cartography Biosciences
Phase 1
80
Arizona, California, Florida, Georgia, Michigan, Texas, Virginia
2026-01-15
Recruiting
Eli Lilly and Company
Phase 3
150
California, Florida, Iowa, Kentucky, Pennsylvania, Virginia
2026-01-12
Recruiting
Stemline Therapeutics, Inc.
Phase 1
100
Arkansas, Connecticut, Florida, Massachusetts, Michigan, Minnesota, Virginia
2026-01-10
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
DrugCetuximab
Revolution Medicines, Inc.
Phase 1
574
Connecticut, Maryland, Massachusetts, Michigan, New York, Texas, Virginia
2026-01-08
Recruiting
Amicus Therapeutics
Phase 3
8
Georgia, Minnesota, North Carolina, Ohio, Pennsylvania, Virginia
2026-01-08
Not yet open
Adovate
Phase 1
36
Virginia
2026-01-01
Recruiting
Dewpoint Therapeutics
Phase 1
40
Texas, Virginia
2026-01
Not yet open
Milky Way Sensor: Device Validation for Infiltrated Tissues
NCT07311733Infiltration of Peripheral IV Therapy
ivWatch, LLC
Not applicable
28
Virginia
2026-01
Recruiting
Incyte Corporation
Phase 2
56
Arizona, California, Colorado, Connecticut, Florida, Massachusetts, New York, Virginia
2025-12-29
Recruiting
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
NCT07315113EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients
DrugsNXP900·Osimertinib
Nuvectis Pharma, Inc.
Phase 1
18
Maryland, Massachusetts, Oregon, Pennsylvania, Texas, Virginia
2025-12-18
Recruiting
Phase 1 Study of Intravaginal KB15A
NCT07222020Healthy Subjects
ZabBio Inc.
Phase 1
24
Virginia
2025-12-16
Recruiting
Merck Sharp & Dohme LLC
Phase 1
250
New Jersey, Texas, Virginia
2025-12-16
Recruiting
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
NCT07172893Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
HealthTech Wound Care
Phase 4
150
Florida, Michigan, North Carolina, Ohio, Texas, Virginia
2025-12-10
Recruiting
Pfizer
Phase 2/3
550
Arkansas, Florida, Ohio, Texas, Virginia
2025-12-09
Recruiting
Ipsen
Phase 1/2
114
Connecticut, Michigan, Pennsylvania, Texas, Virginia
2025-12-05
By invitation
Tarsus Pharmaceuticals, Inc.
Phase 2
155
Texas, Virginia
2025-12-05
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Maryland, Michigan, Nevada, New Jersey, Utah, Virginia
2025-12-04
Recruiting
Daiichi Sankyo
Phase 1
60
California, Massachusetts, Michigan, New York, South Carolina, Texas, Virginia, Wisconsin
2025-12-03
Recruiting
Conjupro Biotherapeutics, Inc.
Phase 1
270
North Carolina, Texas, Virginia
2025-12-02
Recruiting
AbbVie
Phase 1
285
California, Colorado, Illinois, Nebraska, Texas, Utah, Virginia
2025-11-27
Recruiting
AstraZeneca
Phase 1
40
North Carolina, Texas, Virginia
2025-11-25
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
NCT07223047Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
DrugsCetuximab·Nab-paclitaxel·Gemcitabine·Pembrolizumab
Bristol-Myers Squibb
Phase 1/2
252
Maryland, Texas, Utah, Virginia
2025-11-25
Recruiting
Kuros Biosurgery AG
Not applicable
126
California, Colorado, Georgia, North Carolina, Pennsylvania, Tennessee, Virginia
2025-11-25
Recruiting
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
NCT07300150Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor
DrugCetuximab
PAQ Therapeutics, Inc.
Phase 1
210
Massachusetts, Texas, Utah, Virginia
2025-11-21
Recruiting
Everest Medicines (Beijing) Co., Ltd.
Phase 1/2
94
New York, Texas, Virginia
2025-11-17
Recruiting
Rhaeos, Inc.
Not applicable
28
Illinois, Virginia
2025-11-10
Recruiting
BeOne Medicines
Phase 1
63
Texas, Virginia
2025-11-10
Recruiting
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Massachusetts, New York, Texas, Virginia
2025-11-07
Active, closed
Novo Nordisk A/S
Phase 3
300
California, Colorado, Florida, Illinois, Indiana, Missouri, North Carolina, Virginia
2025-11-05
Recruiting
Shionogi
Phase 2
45
California, Florida, Georgia, Missouri, North Carolina, Ohio, Pennsylvania, Virginia
2025-10-30
Recruiting
Philips Clinical & Medical Affairs Global
Observational
75
Virginia
2025-10-28
Active, closed
Bavarian Nordic
Phase 2
970
Iowa, Kansas, New York, North Carolina, South Carolina, Tennessee, Texas, Virginia
2025-10-27
Recruiting
Solid Biosciences Inc.
Phase 3
80
Arkansas, Texas, Virginia
2025-10-22
Recruiting
ImmunityBio, Inc.
Phase 1/2
40
Arizona, California, Georgia, Michigan, New York, Pennsylvania, Tennessee, Virginia
2025-10-15
Recruiting
Long-Term Stability of the Glide Control Strategy
NCT07222085Upper Limb Amputation Above Elbow, Upper Limb Amputation Below Elbow
Infinite Biomedical Technologies
Not applicable
12
Maryland, Massachusetts, North Carolina, South Carolina, Virginia
2025-10-15
Recruiting
Z1 Hip System: Post-Market Clinical Follow Up Study
NCT07104279Hip Osteoarthritis, Acute Traumatic Fracture of the Femoral Head or Neck, Avascular Necrosis of the Femoral Head
Zimmer Biomet
Observational
300
North Carolina, Ohio, Oregon, Virginia
2025-10-13
By invitation
Novel On-body Evaluation of Cardiac Health for Oncology
NCT07158450Cardiotoxicity, Heart Failure
Skribe Medical
Observational
1,000
Colorado, Florida, Illinois, Louisiana, New York, Pennsylvania, Tennessee, Virginia
2025-10-09
Recruiting
Daiichi Sankyo
Phase 1
192
Florida, Rhode Island, Texas, Virginia
2025-10-02
Recruiting
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT04716452Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory, Refractory/Relapse Acute Myeloid Leukemia
Keystone Nano, Inc
Phase 1
15
Virginia
2025-10-01
Recruiting
Vanda Pharmaceuticals
Phase 2
160
California, Massachusetts, North Carolina, Tennessee, Virginia
2025-10
Active, closed
Stratagen Bio, Inc.
Not applicable
75
New York, Virginia
2025-09-24
Recruiting
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
NCT07136779Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc
Phase 1/2
310
Michigan, Texas, Utah, Virginia
2025-09-23
Recruiting
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
NCT07141706Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1
253
California, Michigan, Pennsylvania, Texas, Virginia
2025-09-23
Recruiting
Cerus Corporation
Phase 2
120
Ohio, Virginia
2025-09-19
Recruiting
Kumquat Biosciences Inc.
Phase 1
78
California, Colorado, Florida, Michigan, Ohio, Texas, Utah, Virginia
2025-09-16
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
NCT06689839Aortic Stenosis Treated With TAVI, Aortic Diseases
EnCompass Technologies, Inc.
Not applicable
500
Florida, Indiana, Michigan, Missouri, New York, Ohio, Virginia
2025-09-09
Recruiting
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
NCT07145255Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell)
MBrace Therapeutics
Phase 1/2
150
California, Michigan, New Jersey, Texas, Utah, Virginia
2025-09-03
Recruiting
Gilead Sciences
Phase 1
476
Massachusetts, Texas, Virginia
2025-08-28
Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
Alentis Therapeutics AG
Phase 1/2
180
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Texas, Virginia
2025-08-26
Recruiting
Azitra Inc.
Phase 1/2
32
Arkansas, Connecticut, New York, Ohio, Texas, Virginia
2025-08-25
Recruiting
Wayshine Biopharm, Inc.
Phase 2
40
California, Florida, Michigan, New Jersey, Ohio, Pennsylvania, Texas, Virginia
2025-08-18
Recruiting
GlaxoSmithKline
Phase 2
220
Florida, New Jersey, New York, North Carolina, Oklahoma, Texas, Virginia
2025-08-14
Recruiting
AstraZeneca
Phase 2
278
California, Georgia, Maryland, Texas, Virginia
2025-08-07
Recruiting
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
120
Michigan, Missouri, Pennsylvania, Texas, Virginia
2025-07-29
Recruiting
Chiesi Farmaceutici S.p.A.
Phase 2/3
22
Arizona, Georgia, Iowa, Ohio, Utah, Virginia
2025-07-29
Recruiting
Merit Medical Systems, Inc.
Observational
100
District of Columbia, Florida, North Carolina, Pennsylvania, Texas, Virginia
2025-07-28
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
California, Colorado, Florida, Tennessee, Texas, Virginia, Washington
2025-07-25
Recruiting
Sanofi
Phase 1/2
32
Florida, New York, Pennsylvania, Virginia
2025-07-23
Active, closed
Insmed Gene Therapy LLC
Phase 1
12
Arkansas, California, Georgia, New York, Ohio, Tennessee, Virginia
2025-07-22
Recruiting
FoRx Therapeutics AG
Phase 1
40
California, Michigan, Missouri, Oregon, Texas, Virginia
2025-07-22
Recruiting
Janssen Research & Development, LLC
Phase 1
400
Florida, New York, Tennessee, Virginia
2025-07-15
Active, closed
Visual Field Analysis With Artificial Intelligence
NCT06920290Glaucoma, Visual Field Defect
Sight Intelligence Engineering Corporation
Observational
100
Virginia
2025-07-01
Recruiting
Evaluation of Cataract Surgery Outcomes in Patients With Prior Laser Vision Correction Implanted With the CT LUCIA Lens
NCT07084545Postoperative Visual Outcomes Following Cataract Surgery in Patients With Prior Myopic Corneal Laser Vision Correction
Carl Zeiss Meditec AG
Observational
30
Texas, Virginia
2025-07
Recruiting
Azafaros B.V.
Phase 3
147
California, Minnesota, Texas, Virginia
2025-06-30
Recruiting
Azafaros B.V.
Phase 3
72
California, Minnesota, Texas, Virginia
2025-06-30
Active, closed
Azafaros B.V.
Phase 3
75
California, Minnesota, Texas, Virginia
2025-06-30
Recruiting
Hoffmann-La Roche
Phase 3
75
California, Florida, Kentucky, Minnesota, Missouri, Virginia
2025-06-27
Active, closed
LifeNet Health
Not applicable
120
Arizona, California, Florida, Illinois, North Carolina, Texas, Virginia
2025-06-26
Recruiting
NGM Biopharmaceuticals, Inc
Phase 2
136
California, Florida, Maryland, New York, Ohio, Texas, Virginia, Wisconsin
2025-06-25
Active, closed
jCyte, Inc
Phase 2
31
Arizona, California, Florida, Illinois, New Jersey, New York, Texas, Virginia
2025-06-20
Recruiting
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
NCT07087613Hypertension, Pulmonary, Heart Failure With Reduced Ejection Fraction
Eko Devices, Inc.
Observational
3,850
Illinois, Virginia
2025-06-15
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
California, Connecticut, Massachusetts, North Carolina, Texas, Virginia, Washington
2025-06-10
Active, closed
Biogen
Phase 3
255
California, Florida, Pennsylvania, Tennessee, Virginia, Washington
2025-06-09
By invitation
Virtuos Bone Graft in Lumbar Fusion
NCT06686017Degenerative Disc Disease
Orthofix Inc.
Observational
150
Indiana, Michigan, Montana, North Carolina, South Carolina, Texas, Virginia
2025-06-05
Recruiting
Chugai Pharmaceutical
Phase 1
130
Michigan, Texas, Virginia
2025-06-05
Recruiting
Erasca, Inc.
Phase 1
600
California, Colorado, Florida, Massachusetts, New York, Texas, Virginia
2025-06-05
Recruiting
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer
Dren Bio
Phase 1
96
Colorado, Florida, North Carolina, Oklahoma, South Carolina, Texas, Virginia
2025-06-03
Recruiting
Merck Sharp & Dohme LLC
Phase 2
160
Arkansas, California, New Jersey, Virginia, Washington
2025-05-29
Recruiting
Merck Sharp & Dohme LLC
Phase 2
144
Kentucky, Maryland, Texas, Virginia
2025-05-28
Recruiting
UroMems SAS
Not applicable
140
California, Minnesota, North Carolina, Ohio, Tennessee, Texas, Virginia
2025-05-19
Recruiting
GC Biopharma Corp
Phase 1/2
18
California, Kansas, Minnesota, Ohio, Pennsylvania, Virginia
2025-05-14
Recruiting
Dizal Pharmaceuticals
Phase 1
140
New York, Virginia
2025-05-13
By invitation
Sanofi
Phase 2
71
California, Idaho, Oklahoma, Texas, Virginia
2025-05-12
Recruiting
Tagworks Pharmaceuticals BV
Phase 1
50
Arizona, Massachusetts, Pennsylvania, Texas, Virginia
2025-05-07
Active, closed
Vanda Pharmaceuticals
Phase 2
50
California, Colorado, Minnesota, Texas, Virginia
2025-05-05
Recruiting
STORM Therapeutics LTD
Phase 1/2
107
California, Florida, Massachusetts, Michigan, New York, Ohio, Texas, Virginia
2025-05-05
Not yet open
Respiratory Oxygen Adherence Monitor for Chronic Obstructive Pulmonary Disease Patients
NCT06874101COPD, COPD - Chronic Obstructive Pulmonary Disease
Barron Associates, Inc.
Not applicable
100
Virginia
2025-05-01
Recruiting
Eikon Therapeutics
Phase 1/2
130
Colorado, Florida, Massachusetts, Texas, Virginia
2025-04-30
Recruiting
Gilead Sciences
Phase 1/2
100
California, Georgia, Kansas, Missouri, Tennessee, Texas, Virginia
2025-04-30
By invitation
Vertex Pharmaceuticals Incorporated
Phase 2
44
Missouri, North Carolina, Virginia
2025-04-28
Recruiting
Access Cannulation Trial II
NCT05490225Dialysis; Complications, Vascular Access Complication
Voyager Biomedical
Not applicable
100
Alabama, California, Massachusetts, New York, South Carolina, Texas, Virginia
2025-04-23
Recruiting
Endomagnetics Ltd.
Observational
184
North Carolina, Virginia
2025-04-22
Recruiting
GlaxoSmithKline
Phase 3
911
Arizona, California, Florida, Idaho, Ohio, Texas, Virginia
2025-04-17
By invitation
Regeneron Pharmaceuticals
Phase 2
48
California, Colorado, Kansas, Michigan, New Jersey, Tennessee, Texas, Virginia
2025-04-14
Active, closed
Hoffmann-La Roche
Phase 2
30
Arkansas, California, Georgia, Michigan, Texas, Virginia
2025-04-04
Recruiting
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
NCT06346600Neovascular (Wet) Age-related Macular Degeneration
Skyline Therapeutics
Observational
83
Massachusetts, Texas, Virginia
2025-04-02
Active, closed
Merck Sharp & Dohme LLC
Phase 2
160
Connecticut, District of Columbia, Florida, Montana, New Jersey, Ohio, Virginia, Wisconsin
2025-04-01
Not yet open
Pearsanta, Inc
Observational
1,000
Virginia
2025-04
Recruiting
Prescient Therapeutics, Ltd.
Phase 2
115
California, Connecticut, Massachusetts, New York, Virginia
2025-03-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Alabama, Florida, New Jersey, Texas, Virginia
2025-03-25
Active, closed
Merck Sharp & Dohme LLC
Phase 2
60
Alabama, California, Colorado, Maryland, Oregon, Texas, Virginia
2025-03-20
Recruiting
Merck Sharp & Dohme LLC
Phase 2
372
California, Illinois, Montana, Oregon, Tennessee, Texas, Virginia
2025-03-20
Recruiting
VDI Technologies
Observational
360
Arizona, Illinois, Minnesota, Ohio, Texas, Virginia
2025-03-18
Active, closed
Ipsen
Phase 1/2
42
Michigan, Tennessee, Texas, Utah, Virginia
2025-03-14
Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
NCT06835569Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
DrugsCisplatin/Carboplatin·MFOLFIRINOX·MFOLFOX6·Midazolam
Alterome Therapeutics, Inc.
Phase 1
448
Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee, Texas, Virginia
2025-03-05
Active, closed
BicycleTx Limited
Phase 2
66
Maryland, Massachusetts, Missouri, New York, North Carolina, Oregon, Texas, Virginia
2025-03-03
Active, closed
A Phase 2 in Adult Subjects With Hereditary Angioedema
NCT06846398Hereditary Angioedema (HAE)
DrugBW-20805
Shanghai Argo Biopharmaceutical Co., Ltd.
Phase 2
25
Maryland, Missouri, North Carolina, Pennsylvania, Virginia
2025-02-28
Recruiting
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
NCT06816992Solid Tumors, EGFR Exon 20 Insertion Mutations, NSCLC, EGFR-mutated NSCLC
DrugAmivantamab
ORIC Pharmaceuticals
Phase 1
76
New York, Virginia
2025-02-27
Recruiting
Hansoh BioMedical R&D Company
Phase 1
475
Florida, Indiana, North Carolina, Texas, Virginia
2025-02-26
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
181
Colorado, Massachusetts, New Jersey, South Carolina, Virginia
2025-02-26
Recruiting
Vividion Therapeutics, Inc.
Phase 1
220
Michigan, Texas, Utah, Virginia
2025-02-25
Active, closed
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
NCT06770933Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Vantage Biosciences Ltd
Phase 2
100
California, Florida, Georgia, Maryland, Oregon, Pennsylvania, Virginia
2025-02-11
Recruiting
Shanghai Allink Biotherapeutics Co., Ltd.
Phase 1
234
Florida, Virginia
2025-02-10
Active, closed
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
NCT06678074STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI), Stent Implantation
Implicit Bioscience
Phase 1/2
10
Missouri, Virginia
2025-02-06
Recruiting
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
NCT06805825Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma
Novelty Nobility, Inc.
Phase 1
67
Michigan, Ohio, Oregon, Texas, Virginia
2025-02-03
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
California, District of Columbia, Florida, South Carolina, Tennessee, Texas, Virginia
2025-01-29
Active, closed
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
NCT06781983Advanced or Metastatic Solid Tumors
Innate Pharma
Phase 1
145
Massachusetts, New Jersey, New York, Texas, Virginia
2025-01-24
Recruiting
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2
84
Arizona, California, Texas, Virginia, Washington
2025-01-23
Active, closed
AbbVie
Phase 1
21
North Carolina, Oregon, Texas, Utah, Virginia
2025-01-16
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1
250
California, New Jersey, Texas, Virginia
2025-01-10
Recruiting
Compugen Ltd
Phase 1
200
Connecticut, Massachusetts, Michigan, Tennessee, Texas, Virginia
2025-01-07
Recruiting
Adcentrx Therapeutics
Phase 1
68
California, Michigan, Minnesota, Texas, Utah, Virginia
2024-12-30
Recruiting
Skye Biologics Holdings, LLC
Not applicable
100
Virginia
2024-12-28
Recruiting
Skye Biologics Holdings, LLC
Not applicable
100
Virginia
2024-12-28
Recruiting
PAQ Therapeutics, Inc.
Phase 1
300
California, Massachusetts, Michigan, Tennessee, Texas, Utah, Virginia
2024-12-19
Recruiting
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AG
Phase 1/2
170
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Virginia
2024-12-16
Recruiting
Novartis Pharmaceuticals
Phase 3
60
California, District of Columbia, Florida, New York, Utah, Virginia, West Virginia
2024-12-09
Active, closed
SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization
NCT06550024Osteo Arthritis Knee, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
CrannMed
Not applicable
89
Alabama, California, Florida, North Carolina, Virginia
2024-11-28
Active, closed
AbbVie
Observational
1,314
Alabama, Arizona, California, Florida, Kentucky, New York, Pennsylvania, Virginia
2024-11-26
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,380
Connecticut, Michigan, Missouri, New York, Texas, Virginia, Washington
2024-11-25
Recruiting
Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers
NCT06681428Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Tides Medical
Not applicable
240
California, Florida, North Carolina, Ohio, Virginia
2024-11-14
Recruiting
GigaGen, Inc.
Phase 1
48
Arizona, California, Georgia, Iowa, Kansas, Maryland, Texas, Virginia
2024-11-13
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
12
District of Columbia, Virginia
2024-11-13
Active, closed
Noah Medical
Observational
50
Tennessee, Virginia
2024-11-08
Recruiting
Chiesi Farmaceutici S.p.A.
Observational
100
Alabama, Georgia, Illinois, Iowa, Michigan, Virginia
2024-11-06
Recruiting
A Study of DM005 in Patients With Advanced Solid Tumors
NCT06515990Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma
Doma Biopharmaceutical（Suzhou）Co., Ltd.
Phase 1/2
208
Michigan, Texas, Virginia
2024-10-31
Active, closed
Daiichi Sankyo
Phase 1/2
137
California, Florida, Kentucky, Minnesota, New York, Pennsylvania, Virginia
2024-10-30
Active, closed
A Study of ZW191 in Participants With Solid Tumors
NCT06555744Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1
145
Connecticut, Ohio, Oklahoma, Texas, Virginia
2024-10-30
Recruiting
BeOne Medicines
Phase 1
153
New Jersey, Texas, Virginia, Wisconsin
2024-10-18
Active, closed
IC14 for Treatment of Acute Decompensated Heart Failure
NCT06556810Acute Decompensated Heart Failure
DrugAtibuclimab
Implicit Bioscience
Phase 1/2
10
Virginia
2024-10-17
Recruiting
Study of ATX-01 in Participants With DM1
NCT06300307Myotonic Dystrophy 1
ARTHEx Biotech S.L.
Phase 1/2
56
California, Florida, Iowa, Kansas, Virginia
2024-10-15
Active, closed
Hologic, Inc.
Not applicable
75
Texas, Virginia
2024-10-14
Recruiting
Yuhan Corporation
Phase 1/2
201
Virginia
2024-10-02
Recruiting
FUSMobile Inc.
Not applicable
10
Virginia
2024-09-13
Recruiting
NaviFUS Corporation
Phase 1/2
8
California, Massachusetts, Virginia
2024-09-13
Recruiting
Bone Mineral Density Agreement Study Between EOSedge™ Versus Traditional DXA
NCT06659055Healthy, Indicated for EOSedge Imaging
Alphatec Spine, Inc.
Not applicable
214
Arizona, California, Tennessee, Virginia
2024-09-11
Recruiting
ModernaTX, Inc.
Phase 4
1,144
Georgia, Louisiana, Mississippi, Nebraska, Virginia
2024-09-09
Active, closed
TransCode Therapeutics
Phase 1/2
16
Texas, Utah, Virginia
2024-09-05
Recruiting
Study With [225Ac]Ac-FL-020 in mCRPC Participants
NCT06492122Metastatic Castration-resistant Prostate Cancer
DrugBlood samples for PK
Full-Life Technologies UK Limited
Phase 1
50
California, Ohio, Virginia
2024-08-30
Active, closed
argenx
Phase 2
33
Alabama, California, Illinois, Nebraska, North Carolina, Ohio, Virginia, Washington
2024-08-30
Recruiting
Janssen Research & Development, LLC
Phase 2
210
California, Colorado, Connecticut, New York, North Carolina, Ohio, Virginia, Washington
2024-08-26
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia
2024-08-22
Active, closed
Rgenta Therapeutics Inc
Phase 1
105
Massachusetts, Michigan, New York, Texas, Virginia, Washington
2024-08-19
Recruiting
Carrick Therapeutics Limited
Phase 1/2
50
Texas, Virginia
2024-08-16
Recruiting
Gilead Sciences
Phase 1
154
California, Massachusetts, Texas, Virginia
2024-07-26
Recruiting
Endocardial Mapping With the CoreMap EP Mapping System
NCT06529978Persistent Atrial Fibrillation
CoreMap Inc.
Not applicable
245
Florida, Vermont, Virginia
2024-07-25
Recruiting
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
NCT06440005Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
Angiex, Inc.
Phase 1
80
California, Florida, Missouri, Tennessee, Texas, Virginia
2024-07-22
Active, closed
Regeneron Pharmaceuticals
Phase 2
195
Florida, Illinois, Kansas, Michigan, Missouri, New York, Oregon, Virginia
2024-07-16
Recruiting
Biotheryx, Inc.
Phase 1
82
Minnesota, Nebraska, Texas, Utah, Virginia
2024-07-03
Active, closed
Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia
NCT06449378Hernia, Hernia, Ventral, Hernia, Abdominal, Hernia Abdominal Wall
Medtronic - MITG
Not applicable
163
Illinois, Kentucky, North Carolina, Ohio, Virginia
2024-07-02
Recruiting
argenx
Phase 2/3
12
North Carolina, Texas, Virginia
2024-06-28
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1
63
California, Colorado, Florida, Michigan, New York, Texas, Virginia, Washington
2024-06-24
Recruiting
Alessa Therapeutics Inc.
Phase 1
45
California, Illinois, Louisiana, Maryland, Oregon, South Carolina, Virginia, Wisconsin
2024-06-21
Recruiting
Atrial Flutter Ablation in the iCMR
NCT05904548Atrial Flutter Typical
Imricor Medical Systems
Not applicable
91
Maryland, Virginia
2024-06-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
California, Colorado, District of Columbia, Florida, Georgia, New York, Texas, Virginia
2024-06-20
Recruiting
Aprea Therapeutics
Phase 1
90
New Jersey, Ohio, Texas, Virginia
2024-06-13
Active, closed
OBI Pharma, Inc
Phase 1/2
117
California, Michigan, Texas, Virginia
2024-06-12
Recruiting
Kuros Biosurgery AG
Not applicable
100
Connecticut, Illinois, Maryland, Michigan, North Carolina, Ohio, Utah, Virginia
2024-06-10
Recruiting
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
NCT06332755Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial Carcinoma
LG Chem
Phase 1
76
Virginia
2024-06-05
Active, closed
Kumquat Biosciences Inc.
Phase 1
92
Colorado, Florida, Michigan, New York, Ohio, Tennessee, Texas, Virginia
2024-06-03
Active, closed
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT06328738HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification
DrugsELVN-002·Eribulin·Leucovorin·Trastuzumab
Enliven Therapeutics
Phase 1
275
Florida, Missouri, Virginia
2024-05-30
Recruiting
NX Development Corp
Phase 3
170
Arizona, Florida, Maryland, Minnesota, New York, Ohio, Pennsylvania, Virginia
2024-05-30
Active, closed
Philogen S.p.A.
Phase 2
90
Illinois, Massachusetts, New York, Pennsylvania, Texas, Virginia
2024-05-22
Active, closed
Spur Therapeutics
Phase 1/2
75
Virginia
2024-05-13
Recruiting
Genprex, Inc.
Phase 1/2
62
Colorado, Missouri, Ohio, Oregon, Texas, Virginia, Washington
2024-05-09
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926Melanoma Stage IV, Solid Tumor
Georgiamune Inc
Phase 1/2
117
Arizona, California, Massachusetts, Montana, New York, Ohio, Tennessee, Virginia
2024-05-09
By invitation
Long Term Follow-up for RGX-202
NCT06491927Duchenne Muscular Dystrophy
REGENXBIO Inc.
Observational
66
Arkansas, California, Illinois, Texas, Virginia
2024-05-08
Recruiting
Tyligand Pharmaceuticals (Suzhou) Limited
Phase 1/2
440
Texas, Virginia
2024-04-29
Recruiting
Daiichi Sankyo
Phase 1/2
680
California, Illinois, Minnesota, New York, Tennessee, Texas, Utah, Virginia
2024-04-10
Active, closed
Medtronic - MITG
Not applicable
206
Florida, Illinois, New York, North Carolina, Ohio, Texas, Virginia
2024-04-08
Active, closed
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Ipsen
Phase 1/2
36
California, Connecticut, Tennessee, Virginia
2024-04-03
Recruiting
CytomX Therapeutics
Phase 1
160
Colorado, Massachusetts, New York, North Carolina, Tennessee, Texas, Virginia
2024-04-02
Active, closed
Urotronic Inc.
Observational
500
Florida, Nebraska, Nevada, New York, Oregon, Texas, Virginia
2024-03-30
Active, closed
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer
Nuvation Bio Inc.
Phase 1/2
466
Michigan, New Jersey, New York, North Carolina, Texas, Utah, Virginia, Washington
2024-03-14
Recruiting
PAS-004 in Patients With Advanced Solid Tumors
NCT06299839RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
DrugPAS-004
Pasithea Therapeutics Corp.
Phase 1
48
Texas, Virginia
2024-02-29
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant
OnKure, Inc.
Phase 1
200
California, Colorado, Massachusetts, Nevada, New York, Tennessee, Virginia, Washington
2024-02-26
Recruiting
Skyline Therapeutics (US) Inc.
Phase 1/2
68
Florida, Massachusetts, Texas, Virginia
2024-02-23
Active, closed
AstraZeneca
Phase 2
142
New York, Texas, Virginia
2024-02-22
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 1/2
47
California, Florida, Kansas, Massachusetts, Missouri, North Carolina, Pennsylvania, Virginia
2024-02-20
Active, closed
Boehringer Ingelheim
Phase 1
69
District of Columbia, Florida, Virginia
2024-02-14
Recruiting
Endoron Medical
Not applicable
25
Virginia
2024-02-06
Recruiting
Claris Biotherapeutics, Inc.
Phase 1
20
California, Indiana, Minnesota, Oregon, Texas, Virginia
2024-02-05
Recruiting
Accuro XV Ultrasound Imaging System for BoneEnhance and Fracture Detection Algorithms
NCT07853768Fracture Arm, Fracture Leg, Wrist Injury, Ankle Injury
Rivanna Medical, Inc.
Not applicable
25,000
California, Colorado, Connecticut, Illinois, Pennsylvania, Texas, Utah, Virginia
2024-01-29
Recruiting
STIMIT Activator 1 IDE Study
NCT05883163Diaphragm Issues
Stimit AG
Not applicable
40
Connecticut, Massachusetts, Virginia
2024-01-24
Recruiting
NextPoint Therapeutics, Inc.
Phase 1
144
Maryland, Massachusetts, New York, Texas, Virginia
2024-01-22
Recruiting
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
NCT06059963Colorectal Cancer, Advanced Adenocarcinoma
Universal Diagnostics
Observational
12,000
Virginia
2024-01-18
Recruiting
AstraZeneca
Phase 1/2
334
California, Connecticut, Maryland, Oregon, Pennsylvania, Rhode Island, Virginia
2024-01-18
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
17
California, Ohio, Pennsylvania, Virginia
2024-01-15
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Alabama, California, Florida, Georgia, Illinois, New York, Texas, Virginia
2023-12-29
Recruiting
IO Biotech
Phase 2
60
Connecticut, Massachusetts, Virginia
2023-12-21
Recruiting
A Study of LM-24C5 For Advanced Solid Tumors
NCT06187402Advanced Solid Tumor
DrugLM-24C5
LaNova Medicines Limited
Phase 1/2
49
California, Florida, Indiana, Ohio, Texas, Virginia
2023-12-20
Recruiting
1ST Biotherapeutics, Inc.
Phase 1/2
151
Ohio, Texas, Virginia, Washington
2023-12-13
Recruiting
Georgiamune Inc
Phase 1/2
111
California, Florida, Kentucky, New Jersey, Tennessee, Texas, Virginia
2023-12-12
Recruiting
AstraZeneca
Phase 1/2
226
California, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Virginia
2023-12-05
Active, closed
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
NCT06005740Advanced Solid Tumor, Hepatocellular Carcinoma
TORL Biotherapeutics, LLC
Phase 1
70
Arizona, California, Florida, Minnesota, Virginia
2023-12-04
Active, closed
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
67
Georgia, New Jersey, New York, Oregon, Pennsylvania, Virginia
2023-11-27
Recruiting
FetalEase Ltd.
Not applicable
80
Florida, Idaho, North Carolina, Virginia
2023-11-15
Recruiting
Jazz Pharmaceuticals
Phase 1
177
California, Colorado, Florida, North Carolina, Pennsylvania, Tennessee, Texas, Virginia
2023-11-07
Recruiting
Kiromic BioPharma Inc.
Phase 1
48
Arizona, California, Pennsylvania, Texas, Virginia
2023-11-07
Recruiting
MISHA Post-Market Clinical Study
NCT06118892Osteo Arthritis Knee
Moximed
Not applicable
120
California, North Carolina, Oregon, Virginia
2023-11-03
Recruiting
A2A Pharmaceuticals Inc.
Phase 1
86
Michigan, Oklahoma, South Carolina, Texas, Virginia
2023-11-02
Active, closed
Gravitas Medical, Inc.
Not applicable
100
California, Georgia, Massachusetts, Rhode Island, Virginia
2023-10-27
Recruiting
Orion Corporation, Orion Pharma
Phase 1/2
315
California, Missouri, New York, Pennsylvania, Texas, Virginia
2023-10-26
Recruiting
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT06090266Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer
DrugCemiplimab
OncoResponse, Inc.
Phase 1/2
168
Texas, Virginia
2023-10-24
Active, closed
GlaxoSmithKline
Phase 1/2
42
California, Missouri, Texas, Virginia
2023-10-24
Active, closed
Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study
NCT05868148Rotator Cuff Tears, Rheumatoid Arthritis Shoulder, Osteoarthritis Shoulder, Avascular Necrosis of the Head of Humerus
Stryker Trauma and Extremities
Observational
200
California, Ohio, Texas, Virginia
2023-10-20
Recruiting
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
DrugCemiplimab
OncoNano Medicine, Inc.
Phase 1
168
California, Florida, Ohio, Pennsylvania, Texas, Virginia
2023-10-13
Recruiting
Octapharma
Phase 3
30
Alabama, California, Kentucky, Pennsylvania, Texas, Virginia
2023-10-01
Recruiting
Pierre Fabre Medicament
Phase 1/2
345
California, North Carolina, Pennsylvania, Tennessee, Texas, Utah, Virginia
2023-09-26
Active, closed
Treatment of PAF With the Synaptic System
NCT05905835Paroxysmal Atrial Fibrillation
Synaptic Medical Corporation
Not applicable
128
Arizona, Arkansas, California, Missouri, New York, Tennessee, Texas, Virginia
2023-09-20
Active, closed
Venclose digiRF System Post Market Study
NCT05504070Venous Reflux, Chronic Venous Insufficiency
C. R. Bard
Not applicable
203
Colorado, Hawaii, Michigan, New Jersey, North Carolina, Texas, Virginia
2023-09-08
Recruiting
Genfit
Phase 1/2
98
California, Florida, Illinois, New York, Pennsylvania, Texas, Virginia, Wisconsin
2023-08-21
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
437
California, Illinois, Texas, Virginia, Washington
2023-08-10
Active, closed
4D-150 in Patients With Diabetic Macular Edema
NCT05930561Diabetic Macular Edema, Diabetic Retinopathy
DrugsAflibercept IVT·4D-150 IVT·Eylea
4D Molecular Therapeutics
Phase 2
72
Maryland, Oregon, Pennsylvania, Texas, Virginia
2023-08-09
Active, closed
Pfizer
Phase 3
59
Florida, Virginia
2023-08-09
Recruiting
Vividion Therapeutics, Inc.
Phase 1
290
Florida, Minnesota, Tennessee, Texas, Virginia
2023-07-28
Active, closed
Cemented vs Cementless Persona Keel RCT
NCT05630053Knee Pain Chronic, Rheumatoid Arthritis, Osteoarthritis, Traumatic Arthritis
Zimmer Biomet
Not applicable
300
Colorado, Illinois, Maryland, Oregon, Pennsylvania, Virginia
2023-07-25
Recruiting
Hoffmann-La Roche
Phase 1/2
320
California, Connecticut, Florida, New York, Texas, Virginia
2023-06-20
Active, closed
NEUROMARK Registry Study
NCT05937308Chronic Rhinitis
Neurent Medical
Not applicable
150
Alabama, California, Florida, Kentucky, Texas, Utah, Virginia
2023-06-12
Recruiting
Conjupro Biotherapeutics, Inc.
Phase 1
132
California, Colorado, Florida, New Hampshire, Pennsylvania, Tennessee, Texas, Virginia
2023-06-06
Recruiting
LifeNet Health
Observational
100
Alabama, California, Virginia
2023-06-06
Recruiting
ZetrOZ, Inc.
Phase 1
90
Connecticut, Virginia
2023-06-01
Recruiting
Daiichi Sankyo
Phase 1
128
Florida, Rhode Island, Utah, Virginia
2023-05-30
Recruiting
A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer
NCT05930210Diabetic Foot Ulcer, Foot Ulcer, Diabetes Mellitus, Wound
Energenesis Biomedical Co., Ltd.
Phase 3
230
Florida, Georgia, Tennessee, Texas, Utah, Virginia
2023-05-30
Recruiting
Chugai Pharmaceutical
Phase 1
209
Pennsylvania, Rhode Island, Tennessee, Texas, Virginia
2023-05-24
Active, closed
Janssen Research & Development, LLC
Phase 2
68
California, Virginia, Washington
2023-05-18
Active, closed
Janssen Research & Development, LLC
Phase 1/2
71
California, Oregon, Texas, Virginia
2023-05-18
Active, closed
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
NCT05230459Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2, LGMD2I, Muscular Dystrophy
AskBio Inc
Phase 1/2
9
California, Iowa, Kansas, Maryland, Virginia, Washington
2023-05-15
Active, closed
Boehringer Ingelheim
Phase 1
59
California, Colorado, Florida, Michigan, New York, Ohio, Texas, Virginia
2023-05-11
Active, closed
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05789069Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer
DrugTislelizumab
HiFiBiO Therapeutics
Phase 1
83
California, Pennsylvania, Virginia
2023-05-09
By invitation
Guided Therapeutics
Not applicable
400
Alabama, Georgia, Michigan, Virginia
2023-05-05
Recruiting
Chordia Therapeutics, Inc.
Phase 1/2
225
Arizona, Florida, Illinois, Minnesota, New York, Texas, Virginia, Washington
2023-04-25
Active, closed
Regeneron Pharmaceuticals
Phase 2
51
California, Kentucky, New Mexico, New York, North Carolina, Texas, Virginia, Washington
2023-04-21
Active, closed
GlaxoSmithKline
Phase 2
154
California, New Mexico, New York, Pennsylvania, Tennessee, Texas, Virginia
2023-04-03
Active, closed
DEKA Biosciences
Phase 1
39
California, New York, Oklahoma, Texas, Virginia
2023-04-03
Recruiting
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
NCT05856981Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer
DrugsKeytruda·Pembrolizumab
Sairopa B.V.
Phase 1
130
Michigan, Missouri, Ohio, Virginia
2023-04-03
Active, closed
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
NCT05650879HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
DrugsELVN-002·Fam-Trastuzumab Deruxtecan-Nxki·Trastuzumab emtansine·Trastuzumab deruxtecan
Enliven Therapeutics
Phase 1
198
Colorado, Florida, Massachusetts, Virginia
2023-03-20
Active, closed
Prospective Case Registry for Wounds
NCT05898698Wound Healing Delayed
Kerecis Ltd.
Observational
300
Virginia
2023-03-17
Recruiting
Lantern Pharma Inc.
Phase 2
90
California, Pennsylvania, Texas, Virginia
2023-03-01
Active, closed
Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application
NCT05094089Hernia, Ventral, Hernia Incisional, Hernia Incisional Ventral
W.L.Gore & Associates
Observational
320
Georgia, Massachusetts, Michigan, New Mexico, New York, North Carolina, South Carolina, Virginia
2023-02-24
Active, closed
Gilead Sciences
Phase 2
400
Alabama, California, Florida, Illinois, Louisiana, Michigan, Virginia, Washington
2023-02-21
Recruiting
Totus Medicines
Phase 1
241
Illinois, Massachusetts, Nevada, Pennsylvania, Tennessee, Texas, Virginia
2023-02-15
Active, closed
Klus Pharma Inc.
Phase 2
240
Indiana, Kentucky, Maryland, Minnesota, New York, Texas, Virginia
2023-01-17
Recruiting
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT05573126Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
DrugsElacestrant·Exemestane·Everolimus·Abemaciclib
Ellipses Pharma
Phase 1/2
95
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas, Virginia
2023-01-11
Active, closed
Accutar Biotechnology Inc
Phase 1
100
Colorado, Florida, Maryland, Tennessee, Texas, Virginia, Washington
2022-12-29
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
80
Florida, Michigan, Texas, Virginia, Washington
2022-12-20
Active, closed
Prevail Therapeutics
Phase 1/2
8
North Carolina, Virginia
2022-12-20
Active, closed
Novartis Pharmaceuticals
Phase 3
20
Virginia
2022-12-19
Active, closed
Bristol-Myers Squibb
Phase 2/3
230
Florida, New York, Pennsylvania, Texas, Virginia
2022-12-14
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Alabama, California, New York, Virginia
2022-12-13
Active, closed
Dizal Pharmaceuticals
Phase 3
324
California, Colorado, Florida, New York, Ohio, Oregon, Texas, Virginia
2022-12-13
Active, closed
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
Immunitas Therapeutics
Phase 1/2
67
Arizona, Colorado, Florida, Oklahoma, Oregon, Tennessee, Texas, Virginia
2022-11-28
Active, closed
PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs
NCT06051942Benign Prostatic Hyperplasia, Localized Prostate Cancer
PROCEPT BioRobotics
Not applicable
125
California, Illinois, Virginia
2022-11-22
Active, closed
Novartis Pharmaceuticals
Phase 3
568
Colorado, Illinois, Minnesota, North Carolina, Ohio, Oregon, Texas, Virginia
2022-11-21
Active, closed
Cellf Bio LLC
Phase 1
10
Virginia
2022-11-02
Active, closed
Amicus Therapeutics
Phase 3
14
Georgia, Ohio, Virginia
2022-10-31
Active, closed
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
NCT05409976Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis
W.L.Gore & Associates
Not applicable
136
California, District of Columbia, Illinois, Michigan, New York, North Carolina, Virginia
2022-10-25
Recruiting
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
DrugsPF-08046054·Keytruda·Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
714
Alabama, California, Iowa, Michigan, Ohio, Texas, Utah, Virginia
2022-10-25
Active, closed
Nalo Therapeutics Inc.
Phase 1
258
California, Minnesota, Virginia
2022-10-05
Active, closed
Dyne Therapeutics
Phase 1/2
127
California, Florida, Indiana, Iowa, Missouri, New York, Texas, Virginia
2022-09-05
Active, closed
BPGbio
Phase 2
50
California, Massachusetts, New Jersey, New York, Texas, Virginia
2022-08-22
By invitation
argenx
Phase 2/3
12
Illinois, North Carolina, Virginia
2022-08-18
Recruiting
Phanes Therapeutics
Phase 1/2
40
North Carolina, Oklahoma, Tennessee, Texas, Virginia
2022-08-11
Active, closed
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
NCT05335993Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer
DrugsOregovomab·Niraparib
CanariaBio Inc.
Phase 2
10
North Carolina, Oklahoma, Virginia
2022-07-25
Recruiting
Peel Therapeutics Inc
Phase 1
65
Arizona, California, North Carolina, Pennsylvania, Rhode Island, Texas, Utah, Virginia
2022-07-11
Active, closed
Nevro Corp
Not applicable
497
Alaska, Michigan, Ohio, Oklahoma, Oregon, Pennsylvania, Virginia
2022-07-05
Active, closed
Prodeon Medical, Inc
Not applicable
240
Illinois, Virginia
2022-07-05
Active, closed
ArriVent BioPharma, Inc.
Phase 1
160
Arizona, California, Florida, Michigan, Texas, Virginia
2022-06-30
Active, closed
Camurus AB
Phase 2/3
71
Minnesota, New York, Pennsylvania, Texas, Virginia
2022-06-28
Active, closed
Akeso
Phase 2
254
California, Virginia
2022-06-27
Recruiting
AstraZeneca
Phase 1/2
695
California, Illinois, Massachusetts, New York, Oregon, Texas, Virginia
2022-06-24
Recruiting
BioNTech SE
Phase 1
320
Kentucky, Maryland, Ohio, Texas, Virginia
2022-06-17
Active, closed
ProVee Urethral Expander System IDE Study (ProVIDE)
NCT05186740BPH With Symptomatic Lower Urinary Tract Symptoms
ProVerum Medical
Not applicable
221
California, Florida, Illinois, Nevada, New York, North Carolina, Texas, Virginia
2022-06-09
Active, closed
Treadwell Therapeutics, Inc
Phase 1/2
44
Ohio, Texas, Utah, Virginia
2022-05-27
Active, closed
Candela Corporation
Not applicable
500
Florida, Massachusetts, North Carolina, Virginia
2022-05-24
Active, closed
IO Biotech
Phase 3
407
Florida, New York, Virginia
2022-05-17
Active, closed
MedTrace Pharma A/S
Phase 3
215
Iowa, Minnesota, Missouri, Pennsylvania, Texas, Virginia
2022-05-08
Active, closed
Sanofi
Phase 3
104
Alabama, California, Georgia, Illinois, New York, Texas, Utah, Virginia
2022-05-03
Active, closed
US Pilot Study of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
NCT05232838Hydrocephalus, Normal Pressure, Hydrocephalus
CereVasc Inc
Not applicable
50
Connecticut, Florida, Kansas, Kentucky, Massachusetts, New York, Rhode Island, Virginia
2022-04-20
Active, closed
Sanofi
Phase 3
43
Connecticut, Iowa, Texas, Virginia
2022-04-18
Active, closed
Zhuhai Yufan Biotechnologies Co., Ltd
Phase 1
39
Colorado, Florida, Ohio, Texas, Virginia
2022-03-31
Recruiting
A Study in Patients With Advanced Cancers
NCT05320588Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
DrugsKeytruda·Pembrolizumab
BiOneCure Therapeutics Inc.
Phase 1/2
332
Texas, Virginia
2022-03-25
Active, closed
HiFiBiO Therapeutics
Phase 1
72
Arizona, California, Florida, Minnesota, Missouri, Texas, Virginia
2022-03-10
Active, closed
Cardiac Implantable Electronic Device (CIED) Research Study
NCT05061862Arrhythmias, Cardiac, Bradycardia, Tachycardia
Medtronic Cardiac Rhythm and Heart Failure
Observational
1,000
Florida, Georgia, Oregon, Pennsylvania, Virginia
2022-03-06
Recruiting
Trisol System EFS Study
NCT04905017Tricuspid Regurgitation
Trisol Medical
Not applicable
30
California, Georgia, New York, Ohio, Pennsylvania, Tennessee, Virginia
2022-03-02
Recruiting
MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers
NCT04647240Venous Stasis Ulcer, Venous Leg Ulcer
Merakris Therapeutics
Phase 2
80
Arizona, California, Florida, Louisiana, New York, Ohio, Texas, Virginia
2022-02-26
Active, closed
Laekna Limited
Phase 3
256
California, Georgia, Iowa, Mississippi, Vermont, Virginia
2022-02-18
Recruiting
Merit Medical Systems, Inc.
Observational
30
Arizona, Florida, Georgia, Ohio, Texas, Utah, Virginia
2022-02-08
Active, closed
Tumor-induced Osteomalacia Disease Monitoring Program
NCT04783428Tumor-induced Osteomalacia (TIO)
Ultragenyx Pharmaceutical Inc
Observational
23
Connecticut, Indiana, Maryland, Tennessee, Virginia
2022-01-31
Active, closed
Kerecis Ltd.
Observational
200
Virginia
2022-01-27
Active, closed
AstraZeneca
Phase 1/2
36
Ohio, Pennsylvania, Texas, Virginia
2022-01-21
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsEvorpacept·Ramucirumab·Herceptin·Taxol
ALX Oncology Inc.
Phase 2/3
127
California, Tennessee, Virginia, Washington
2022-01-15
Active, closed
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
NCT05199272Solid Tumor, Clear Cell Renal Cell Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer
23andMe, Inc.
Phase 1/2
141
California, Georgia, Michigan, New York, Oregon, Tennessee, Texas, Virginia
2021-12-29
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Florida, Michigan, New Jersey, New York, Virginia, Wisconsin
2021-12-17
Active, closed
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
NCT05163028Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
HUYABIO International, LLC.
Phase 1
42
California, Florida, Ohio, Texas, Virginia
2021-12-13
Active, closed
Overseas Pharmaceuticals, Ltd.
Phase 3
500
California, Florida, South Carolina, Virginia
2021-12-10
Active, closed
Rebiscan, Inc.
Observational
200
Virginia
2021-12-01
Recruiting
Pediatric Post-Approval Registry
NCT04457154Obstructive Sleep Apnea
Inspire Medical Systems, Inc.
Observational
60
Colorado, Georgia, North Carolina, Ohio, Pennsylvania, Texas, Virginia
2021-11-30
Recruiting
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
DrugTORL-1-23
TORL Biotherapeutics, LLC
Phase 1
90
California, Kentucky, Minnesota, New York, Ohio, Texas, Virginia
2021-11-17
Active, closed
BicycleTx Limited
Phase 1/2
200
Iowa, New York, Ohio, Pennsylvania, Texas, Virginia
2021-11-02
Recruiting
argenx
Phase 2/3
12
Illinois, North Carolina, Virginia
2021-10-26
Active, closed
JOTEC GmbH
Observational
108
Pennsylvania, Texas, Virginia
2021-10-20
Active, closed
A Long-term Extension Study of Ustekinumab in Pediatric Participants
NCT05092269Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic
DrugUstekinumab
Janssen Research & Development, LLC
Phase 3
159
Georgia, New York, North Carolina, Virginia
2021-10-18
Active, closed
Hoffmann-La Roche
Phase 2
176
California, Missouri, North Carolina, Ohio, Oklahoma, Texas, Virginia, Washington
2021-10-07
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
DrugPaclitaxel
Nurix Therapeutics, Inc.
Phase 1
345
California, Colorado, Illinois, North Carolina, Oklahoma, Texas, Virginia, Washington
2021-09-29
Recruiting
First in Human, Dose Escalation Study of AN4005
NCT04999384Advanced Solid Tumor, Advanced Lymphoma
Adlai Nortye Biopharma Co., Ltd.
Phase 1
31
New Jersey, New York, South Carolina, Virginia
2021-09-27
Active, closed
Orthofix Inc.
Observational
2,000
California, Louisiana, Mississippi, North Carolina, Rhode Island, Utah, Virginia
2021-09-15
Active, closed
AstraZeneca
Phase 1/2
212
Illinois, Minnesota, Virginia
2021-09-14
Active, closed
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT04782687Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell
DrugsDarzalex·Selinexor·Daratumumab·Lenalidomide
US Oncology Research
Phase 2
73
Arizona, Colorado, Maryland, New York, Oregon, Texas, Virginia
2021-09-10
Recruiting
AMO Pharma Limited
Phase 2/3
76
Arkansas, California, Illinois, Iowa, New York, Pennsylvania, Utah, Virginia
2021-08-23
Active, closed
Long-Term Follow-up of Subjects Who Were Treated With ST-920
NCT05039866Fabry Disease, Fabry Disease, Cardiac Variant
Sangamo Therapeutics
Observational
32
California, Florida, Georgia, Iowa, Minnesota, New York, Ohio, Virginia
2021-08-16
Active, closed
Prevail Therapeutics
Phase 1/2
7
California, Minnesota, New York, Pennsylvania, Virginia
2021-06-29
Active, closed
Inspire Medical Systems, Inc.
Not applicable
57
Georgia, Massachusetts, Ohio, Pennsylvania, Texas, Virginia, Wisconsin
2021-06-24
Active, closed
NS Pharma, Inc.
Phase 4
9
California, Illinois, North Carolina, Virginia
2021-06-10
Recruiting
Safety, Efficacy, & Use of ViviGen Cellular Bone Matrix Allograft in Orthopaedic Fracture Care
NCT04299022Fractures, Bone, Nonunion of Fracture, Fractures, Open, Fractures, Ununited
LifeNet Health
Observational
250
Florida, New Jersey, North Carolina, Virginia
2021-06-01
Active, closed
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
DrugsBispecific·Tagrisso·Osimertinib
Merus B.V.
Phase 1/2
194
California, Tennessee, Utah, Virginia
2021-04-28
Recruiting
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes
NCT04786262Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
DrugZimislecel
Vertex Pharmaceuticals Incorporated
Phase 3
57
California, Florida, Illinois, Maryland, Massachusetts, Pennsylvania, Texas, Virginia
2021-03-29
Recruiting
Vivace Therapeutics, Inc
Phase 1/2
434
California, Illinois, Massachusetts, Minnesota, New York, Texas, Virginia
2021-03-24
Recruiting
AstraZeneca
Phase 1
304
California, Kansas, Maryland, Michigan, New York, Texas, Virginia, Washington
2021-03-09
Active, closed
BioNTech SE
Phase 2
327
California, Indiana, Minnesota, Ohio, Rhode Island, Tennessee, Texas, Virginia
2021-03-08
Active, closed
AbbVie
Phase 1
81
Massachusetts, Missouri, North Carolina, Rhode Island, Texas, Virginia
2021-02-23
Active, closed
ML Bio Solutions, Inc.
Phase 2
14
Virginia
2021-02-18
Recruiting
PANTHER Study of Terumo Aortic Knitted and Woven Grafts, and Cardiovascular Patches
NCT04545502Aneurysm, Dissection, Aortic Root Aneurysm, Aortic Root Dissection
Vascutek Ltd.
Observational
2,000
Colorado, Florida, Indiana, North Carolina, Ohio, Pennsylvania, Virginia
2021-02-17
Active, closed
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
NCT04736173Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
DrugsDomvanalimab·Zimberelimab·Pemetrexed·Paclitaxel
Arcus Biosciences, Inc.
Phase 2
169
Georgia, Texas, Virginia
2021-02-08
Active, closed
AstraZeneca
Phase 1
155
California, Missouri, New Jersey, Ohio, Pennsylvania, Texas, Virginia
2021-02-02
Recruiting
AB Science
Phase 3
495
Alabama, California, Kentucky, Maryland, Massachusetts, Virginia
2021-02-02
Active, closed
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
DrugTrastuzumab deruxtecan
AstraZeneca
Phase 2
102
California, Indiana, Massachusetts, New Jersey, New York, Texas, Virginia
2020-12-30
Active, closed
AstraZeneca
Phase 1/2
245
Florida, New York, Ohio, Tennessee, Texas, Virginia
2020-12-28
Active, closed
GC Biopharma Corp
Phase 3
24
Colorado, Texas, Virginia
2020-12-21
Active, closed
AstraZeneca
Phase 3
358
California, Massachusetts, New Hampshire, New York, Texas, Virginia, Washington
2020-12-16
Recruiting
Evaluate the Continued Safety and Performance of the Foot and Ankle Products
NCT04715139Hyperpronated Foot, Reconstruction Surgeries of the Foot, Fixation of Fractures and Fusion (Bunionectomy Osteotomies) of the Foot/Ankle, Fixation of Small Bone Fragments of the Foot/Ankle
Arthrex, Inc.
Observational
700
California, Illinois, Tennessee, Texas, Virginia
2020-12-01
Active, closed
AstraZeneca
Phase 3
640
Georgia, Kentucky, Texas, Virginia, West Virginia
2020-10-19
Active, closed
Mural Oncology, Inc
Phase 1/2
78
Michigan, Texas, Utah, Virginia
2020-09-30
Recruiting
ImmVira Pharma Co. Ltd
Phase 1/2
30
Arizona, Massachusetts, Pennsylvania, Texas, Virginia
2020-09-17
Active, closed
ADC Therapeutics S.A.
Phase 3
440
California, Florida, Iowa, Kentucky, Nevada, Oregon, South Carolina, Virginia
2020-09-16
Active, closed
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
DrugsPF-07104091·Palbociclib·Letrozole·Fulvestrant
Pfizer
Phase 2
157
Iowa, Kentucky, Massachusetts, New Jersey, New York, Virginia
2020-09-16
Active, closed
Medaxis, LLC
Not applicable
222
California, Florida, Maryland, North Carolina, Ohio, Virginia
2020-09-11
Active, closed
4D Molecular Therapeutics
Phase 1/2
18
California, Georgia, Pennsylvania, Virginia
2020-09-01
Recruiting
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
NCT04054310NASH - Nonalcoholic Steatohepatitis
Perspectum
Not applicable
225
Arizona, Illinois, Indiana, New York, Texas, Virginia
2020-08-05
By invitation
Cervical Interbody Implant Study
NCT04689854Degenerative Disc Disease, Cervical Spinal Instability
NuVasive
Observational
150
California, Connecticut, Massachusetts, Missouri, North Carolina, Ohio, Virginia
2020-07-07
Active, closed
InSightec
Not applicable
51
California, Maryland, New York, Ohio, Pennsylvania, Virginia, West Virginia
2020-06-30
By invitation
Cleerly, Inc.
Observational
15,000
Virginia
2020-06-01
Active, closed
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
NCT04152499Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
DrugSacituzumab tirumotecan
Klus Pharma Inc.
Phase 1/2
1,410
California, Florida, Michigan, Oklahoma, Oregon, Texas, Virginia
2020-02-28
Active, closed
Amicus Therapeutics
Phase 3
21
Florida, Georgia, Missouri, North Carolina, Ohio, Pennsylvania, Utah, Virginia
2020-02-13
Active, closed
Takeda
Phase 3
354
California, Florida, Illinois, Maryland, Massachusetts, Tennessee, Virginia
2020-01-10
Recruiting
Kaneka Medical America LLC
Not applicable
35
California, Delaware, Michigan, New York, North Carolina, Ohio, South Carolina, Virginia
2020-01-01
Recruiting
Medtronic Cardiac Surgery PMCF Registry
NCT04073420Valve Disease, Heart
Medtronic Cardiac Surgery
Observational
2,700
Georgia, Michigan, New York, North Carolina, Ohio, Pennsylvania, Texas, Virginia
2019-12-02
Active, closed
Zephyr Valve Registry (ZEVR)
NCT04186546Emphysema
Pulmonx Corporation
Observational
150
Alabama, Illinois, Michigan, Pennsylvania, Texas, Virginia, Wisconsin
2019-11-25
Active, closed
Biogen
Phase 3
152
California, North Carolina, Virginia
2019-10-18
Active, closed
MDR - Biomet Cannulated Screws
NCT04002518Fractures, Bone, Fracture Multiple
Zimmer Biomet
Observational
51
Indiana, Ohio, Virginia
2019-08-07
Active, closed
Bristol-Myers Squibb
Phase 3
839
California, Colorado, Illinois, New York, Oregon, Pennsylvania, Texas, Virginia
2019-08-05
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
California, Colorado, Florida, Massachusetts, Michigan, New York, Ohio, Virginia
2019-07-09
Recruiting
Two Dose Levels of Privigen in Pediatric CIDP
NCT03684018Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CSL Behring
Phase 4
30
Arizona, California, Iowa, Ohio, Pennsylvania, Tennessee, Texas, Virginia
2019-02-28
Active, closed
Study of NEO-201 in Solid Tumors Expansion Cohorts
NCT03476681Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
DrugPembrolizumab
Precision Biologics, Inc
Phase 1/2
121
Maryland, Virginia
2019-01-18
Active, closed
AstraZeneca
Phase 1/2
243
Arizona, Maryland, Massachusetts, Michigan, Missouri, Texas, Virginia
2018-12-21
Active, closed
Post-Market Study of Comprehensive Reverse Augmented Glenoid and Mini Humeral Tray in Total Shoulder Arthroplasty
NCT03726554Arthropathy of Shoulder Region, Grossly Deficient Rotator Cuff, Osteoarthritis of the Shoulder, Rheumatoid Arthritis Without Humeral Metaphyseal Defects
Zimmer Biomet
Not applicable
99
Florida, Kentucky, Michigan, New York, Tennessee, Virginia
2018-08-28
Active, closed
Spark Therapeutics, Inc.
Observational
29
Massachusetts, Mississippi, Missouri, Oregon, Pennsylvania, Virginia
2018-08-14
Active, closed
MedImmune LLC
Phase 1
400
Michigan, New York, North Carolina, Rhode Island, Tennessee, Virginia
2018-04-24
Recruiting
CardioFocus HeartLight Post-Approval Study
NCT03168659Atrial Fibrillation
CardioFocus
Not applicable
250
Arizona, Illinois, New York, Virginia
2017-06-16
Recruiting
CivaTech Oncology
Phase 1/2
80
Florida, Illinois, Louisiana, Pennsylvania, Virginia
2017-05-31
Active, closed
Prospective G7 Dual Mobility Total Hip PMCF
NCT03308929Clinical Outcomes, Functional Outcomes, Radiological Outcomes, Survivorship
Zimmer Biomet
Observational
250
New Jersey, New Mexico, North Carolina, Oregon, Virginia
2017-02-28
Active, closed
AbbVie
Phase 1
163
California, Illinois, Massachusetts, North Carolina, Tennessee, Texas, Virginia
2017-02-22
Active, closed
Genzyme, a Sanofi Company
Phase 2
12
Connecticut, Texas, Virginia
2017-01-04
Active, closed
Janssen Biotech, Inc.
Observational
535
California, Florida, Georgia, Illinois, Ohio, Pennsylvania, Texas, Virginia
2016-12-16
Active, closed
Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:
NCT03100474Essential Tremor, Parkinson's Disease, Movement Disorders, Neuropathic Pain
InSightec
Observational
500
California, Maryland, Pennsylvania, Virginia, Washington
2016-12
Active, closed
A Prospective, Clinical Investigation of the Vanguard 360 Revision Knee
NCT01542580Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Post Traumatic Deformity
Zimmer Biomet
Observational
255
Illinois, Nevada, Utah, Virginia
2012-03
Rows per page Showing 1–485 of 485
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/state/virginia

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 485 of those studies with a site in Virginia.

How many clinical trials are recruiting in Virginia?

289 of the 485 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 18 have not yet opened recruitment, 164 are active but closed to new participants, and 14 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Virginia), 485 studies
PhaseStudiesRecruitingShare
Phase 11319927%
Phase 1/21006620.6%
Phase 2652613.4%
Not applicable603112.4%
Phase 3603212.4%
Observational532410.9%
Phase 2/31172.3%
Phase 4541%

Most active sponsors

Lead sponsors with the most studies (Virginia)
Lead sponsorStudiesRecruiting
AstraZeneca189
Merck Sharp & Dohme LLC1311
AbbVie84
Janssen Research & Development, LLC84
Gilead Sciences76
Zimmer Biomet71
Biogen63
Hoffmann-La Roche64
Pfizer63
argenx52
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.